Deals this week: The Jackson Laboratory (JAX), Boehringer Ingelheim, DiaSorin

1 September 2016 (Last Updated September 1st, 2016 18:30)

The Jackson Laboratory (JAX), a biomedical research institution, and in-vitro diagnostics specialist, BioMerieux USA have announced the signing of a new sponsored research agreement.

Jackson Laboratory precision diagnostics

The Jackson Laboratory (JAX), a biomedical research institution, and in-vitro diagnostics specialist, BioMerieux USA have announced the signing of a new sponsored research agreement.

Pursuant to the agreement, the two companies will develop precision diagnostics for infectious diseases by combining JAX’s expertise in next-generation DNA sequencing and metagenomic analysis, and BioMerieux’s knowledge in clinical microbiology and the biology and detection of microbial resistance.

The companies will devise new methods to detect individuals at risk for infection, the pathogens causing infection, and develop antibiotics that offer the most effective treatment for patients.

With an objective to improve chronic obstructive pulmonary disease (COPD) treatment outcomes, Boehringer Ingelheim Pharmaceuticals has announced a partnership with Qualcomm Life, a subsidiary of Qualcomm.

Through the collaboration, the companies will combine their strengths in healthcare and develop a connectivity solution for Boehringer’s Respimat inhaler.

Qualcomm Life, using its 2net Design platform, will develop the prototype for a small, wireless, low-power, disposable module for the inhaler.

Medical diagnostics company DiaSorin, and Beckman Coulter, a biomedical laboratory instruments manufacturer, have signed an agreement to make the Liaison XL Hepatitis A, B, C and HIV products available in the US market. The products are so far available only to DiaSorin customers outside the US.

Pursuant to the agreement, the companies will get approval for the commercialisation of the products in the US from the Food and Drug Administration (FDA).

"The companies will combine their strengths in healthcare and develop a connectivity solution for Boehringer’s Respimat inhaler."

Once cleared, US customers will get access to the company’s full line of Hepatitis and HIV products that run on the Liaison XL LAS connected to Beckman Coulter’s automation solutions such as Power Express and Power Processor automated processing systems.

DiaSorin will continue commercialising the products as part of its strategy to penetrate the lower volume hospital labs.

Exalenz Bioscience, a non-invasive medical devices developer, and Conatus Pharmaceuticals have announced a partnership, which will enable them to use the former’s non-invasive BreathID Methacetin Breath Test (MBT) to monitor patients with Cirrhosis associated with NASH.

Exalenz's BreathID will be used to monitor patients in a multi-centre, randomised, double-blind, placebo-controlled clinical trial called ENCORE-PH, which is conducted by Conatus to evaluate its investigational treatment, emricasan, for patients with chronic liver disease.

Micro-X, a developer of X-ray products, has announced an exclusive development and supply agreement with Carestream Health, a medical imaging systems provider, for the development and original equipment manufacturer (OEM) supply of a mobile medical X-ray unit.

Pursuant to the agreement, which has a five-year term with an option for annual renewals, the latter will commercialise portable X-ray unit through its network of dealers and distributors.


Image: A woman holding up a petri disk. Photo: courtesy of The Jackson Laboratory.